10 results about "Interleukin 15" patented technology

The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

Provided in the present application are an IL-15 mutant polypeptide, and a preparation method therefor and the use thereof. Further provided are a nucleic acid encoding the IL-15 mutant polypeptide, a vector containing the nucleic acid, and a host cell.

The present invention provides interleukin 15 (IL-15) variants comprising amino acid substitutions for improved homogeneity as well as conjugates and fusion proteins comprising such IL-15 variants. Further, nucleic acids, vectors and host cells for expression of such IL-15 variants as well as pharmaceutical composition comprising such IL-15 variants are provided.

Provided is a cytokine combination useful for treating a tumor and / or preventing recurrence or metastasis of the tumor. The cytokine combination with at least three cytokines selected from the following groups: interleukin 12 (IL12) or a functional variant thereof, granulocyte-macrophage colony-stimulating factor (GMCSF) or a functional variant thereof, FMS-like tyrosine kinase 3 ligand (FLT3L) or a functional variant thereof, interleukin 2 (IL2) or a functional variant thereof, interleukin 15 (IL15) or a functional variant thereof, interleukin 21 (IL21) or a functional variant thereof, and interleukin 7 (IL7) or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and / or preventing recurrence or metastasis of the tumor.

The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administering such agonistic IL-15 complexes.

The invention provides construction, preparation and application of a universal double-target BCMA (bovine serum albumin) / CD19-CAR-DNT (Chimeric Antigen Receptor-DNT) cell with enhanced functions. Specifically, the invention provides a chimeric antigen receptor construct of double-target BCMA / CD19, a membrane binding interleukin 15 (mbIL15) is fused at the C terminal of a bispecific CAR targeting BCMA and CD19 through a self-cleavage peptide, and the CAR construct is introduced into a DNT cell, so that a universal double-target BCMA / CD19-CAR-DNT cell with enhanced functions is obtained. The BCMA / CD19-CAR-DNT cell disclosed by the invention is targeted to BCMA and CD19 at the same time, and has stronger and more lasting cell killing activity, so that a new therapy is provided for BCMA and / or CD19 mediated diseases.

The invention discloses an adeno-associated virus AAV vector. The adeno-associated virus AAV vector comprises a cytokine gene, the cell factor is selected from any one or more than two of the following components: human interleukin 2 (IL2), human interleukin 3 (IL3), human interleukin 6 (IL6), human interleukin 15 (IL15), human thrombopoietin (THPO), human stem cell factor (SCF) and human granulocyte-macrophage colony stimulating factor (GM-CSF). The invention also discloses an AAV vector combination comprising any two or more than three AAV vectors mentioned above. The invention also discloses an application of the AAV vector and a combination of the AAV vector in construction of immune system humanized non-human animals. The invention further discloses a method for constructing the immune system humanized non-human animal.

The present disclosure provides methods and artificial expression constructs for improving the persistence or function of immune cells. In particular, the methods or artificial expression constructs include a mutant interleukin 15 (IL-15) transgene controlled by a constitutive or inducible promoter to enhance the function of immune cells. The mutant IL-15 is modified to concentrate signaling in a cell expressing IL-15R [alpha] and / or a signaling complex comprising IL-15R [alpha]. More specifically, the present disclosure provides methods and artificial expression constructs for enhancing immune cell function by enhancing immune cell proliferation, reducing antigen independent gamma interferon (IFN gamma) release, and inhibiting tumor growth and uncontrolled immune cell proliferation.